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Abstract
Objective: To compare the incidence and profi les of 
misoprostol side effects given per rectal for treating 
postpartum haemorrhage in vaginal delivery versus cesarean 
section.
Methods: A prospective observational study involving 40 
women delivered by vaginal birth (VD) and 40 by Cesarean 
Section (CS) was undertaken in a gynecology ward of a 
hospital in West Java. The incidence of misoprostol’s side 
effects was identifi ed through patient observation and 
medical note review. The side effect probability was rated by 
the panellists of healthcare providers. Patient characteristics 
and side effect data were summarized descriptively. The 
incidence rates of misoprostol’s side effect between the two 
groups were compared using Z-test.
Results: Thirty-four patients (85.0%) in the VD group 
experienced side effects, whilst all CS patients reported at 
least one side effect. There was no signifi cant difference in 
the proportion of patients having side effects in the two 
groups (p=0.366). There were 135 and 164 side effects in 
the VD group and CS group, respectively. There was no 
discernible difference in side effect profi le between the two 
groups. Gastrointestinal side effects accounted for the most 
frequent side effects. Regarding the side effect probability, 
the panellists rated all side effects in VD patients as probable. 
Meanwhile, around70% of side effects in CS patients were 
regarded as probable leaving the remaining as defi nite.
Conclusions:  High incidence of misoprostol’s side effects 
was documented both in VD and CS patients. The incidence 
rates and side effect profi le between the two delivery modes 
were quite similar. 
Keywords: cesarean section,  misoprostol, postpartum 
haemorrhage, side effect, vaginal delivery.
Abstrak
Tujuan: Membandingkan insiden dan profi l efek samping 
misoprostol per rektal untuk pengobatan perdarahan 
pascasalin pada persalinan pervaginam versus seksio 
sesarea.
Metode: Penelitian observasional prospektif melibatkan 40 
perempuan yang melahirkan melalui persalinan pervaginan 
(VD) versus 40 pasien melalui Seksio Sesarea (CS) dilakukan 
di bangsal ginekologi sebuah rumah sakit di Jawa Barat. 
Insiden efek samping misoprostol diidentifi kasi melalui 
pengamatan pasien dan kajian rekam medis. Probabilitas 
efek samping dinilai oleh panel tenaga kesehatan. 
Karakteristik pasien dan profi l efek samping dianalisis secara 
deskriptif. Proporsi insiden efek samping misoprostol antara 
dua metode persalinan dibandingkan menggunakan uji Z.
Hasil: Tiga puluh empat pasien (85,0%) pasien di kelompok 
VD mengalami efek samping, sementara semua pasien 
CS melaporkan setidaknya satu efek samping. Tidak ada 
perbedaan yang signifi kan terkait proporsi pasien yang 
mengalami efek samping di kedua kelompok (p=0,366). 
Secara keseluruhan terdapat 135 dan 164 efek samping pada 
kelompok VD dan CS secara berurutan. Tidak ada perbedaan 
yang nyata dalam profi l efek samping kedua kelompok. Efek 
samping terkait saluran cerna merupakan efek samping 
yang palings sering ditemukan. Terkait probabilitas kejadian 
efek samping, panelis menilai semua efek samping pada 
kelompok VD sebagai “mungkin”. Sementara itu, sekitar 
70% efek samping pada pasien CS dikategorikan “mungkin” 
dan selebihnya “sangat mungkin”.
Kesimpulan: Insiden tinggi efek samping misoprostol 
ditemukan baik pada pasien VD maupun CS. Proporsi 
insiden dan profi l efek samping cukup seragam pada dua 
kelompok tersebut.
Kata kunci: efek samping,  misoprostol, perdarahan pas-
casalin,  persalinan pervaginam, persalinan seksio sesarea.
INTRODUCTION
Primary Postpartum Hamorrhage (PPH) is 
defi ned as blood loss from the genital tract of 
500 mL or more following a normal vaginal 
delivery (NVD) or 1,000 mL or more following a 
cesarean section within 24 hours of birth.1 PPH 
contributes signifi cantly to maternal morbidity 
and mortality. PPH is a leading cause of maternal 
deaths globally, contributing to a quarter of 
the deaths annually.2 In the developed world, 
PPH is a largely preventable and manageable 
condition.3 In developing countries, mortality 
from PPH remains high and recent studies have 
shown that PPH causes up to 60% of all maternal 
death. In Indonesia, PPH is responsible for 43% of 
maternal death cases.4
Some key women’s health organizations 
including International Federation of Gynecology 
and Obstetrics(FIGO), World Health Organization 
(WHO) and Royal College of Obstetricians 
and Gynecologists have supported the use of 
injectable uterotonics (i.e. oxytocin, ergometrine) 
as the fi rst-line treatment for PPH due to their 
effectiveness and safety evidence.5-7  Indonesia 
Society of Obstetrics and Gynecology has 
released its guideline in PPH management which 
was in accordance with the aforementioned 
international organizations.8 Oxytocin and 
ergometrine are proven effective and safe in 
pregnant women even in those with hypertension 
and preeclampsia. Unfortunately, these drugs 
should be administered via injection only and 
require refrigeration to maintain stability. 
Additionally, their administration needs skilled 
health care professionals. These features may 
result in their limited availability particularly in 
a resource-poor environment such as rural and 
isolated areas.9
Misoprostol, a stable prostaglandin E1 
(PGE1) analogue, has been shown to effectively 
stimulate uterine contractility in early pregnancy 
and at term. Misoprostol is known as alternative 
uterotonic agents in a situation where the fi rst-
line treatment is not available and feasible9. This 
drug is registered in Indonesia for the treatment 
of gastric and peptic ulcer. It is not approved yet 
by the Indonesian National Agency of Food and 
Drug Control to be used for the prevention and 
treatment of PPH. However, the use of misoprostol 
in the management of PPH is quite common 
among gynecologists. In low resource settings 
(e.g. developed countries), the use of misoprostol 
has attracted considerable attention due to its 
cheaper price, heat stability and longer half-life as 
opposed to conventional injectable uterotonics 
being used as the fi rst-line treatment for PPH. 
In addition, misoprostol can be administered in 
multiple routes (including oral, buccal, vaginal, 
sublingual and rectal)supporting its ease of 
administration and making it more popular 
in health facilities with limited skilled health 
care providers. Understandably, misoprostol 
was added to Essential Medicines WHO Model 
List for PPH treatment.10 Nevertheless, the 
administration of misoprostol poses certain risks 
to its questionable effectiveness and safety. A 
systematic review of ten randomized-controlled 
trials (RCTs) using oxytocin and misoprostol 
for PPH treatment highlighted that the use of 
misoprostol as an adjunct treatment to oxytocin 
conferred no additional benefi t for patients.11 In 
regards to its safety, misoprostol is frequently 
associated with some transient side effect such as 
chills and pyrexia.12 Moreover, some randomized 
controlled trials of misoprostol have reported 
maternal death and severe morbidity presumably 
linked to its use.13, 14
It has been evident that misoprostol should 
be reserved in certain condition where the fi rst 
line PPH treatment was impractical. However, 
the use of misoprostol for PPH treatment in the 
study hospital was prevalent and not in line with 
the existing evidence where the access to fi rst-
line treatment in the hospital was immediately 
available. It is of importance to note that the side 
effects related to misoprostol ranked third of the 
adverse drug event report in the study hospital. 
Additionally, little research has been undertaken 
to evaluate the side effects of misoprostol in 
two modes of delivery (cesarean versus vaginal 
delivery). Based on the aforementioned reasons, 
the study was conducted to compare the 
incidence and profi le of misoprostol side effects 
in vaginal delivery and cesarean section.
METHODS
This was a prospective observational cohort 
study. Subjects were pregnant women admitted 
to gynecology ward in a district hospital in West 
Java during the period of June-August 2018. 
The inclusion criteria were patients undergoing 
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vaginal delivery or cesarean section who was 
diagnosed with PPH and received misoprostol 
via rectal route within 24 hours of delivery. The 
exclusion criteria were referral patients who 
delivered in other hospitals, those receiving 
misoprostol via other routes in addition to per 
rectal administration and deceased patients. 
Sampling size was calculated using Slovin’s 
formula as follows:
The principal researcher identifi ed the 
occurrence of side effects through patient 
observation and medical note review. The 
probability of side effects was rated by a 
panel consisting of gynecologist, midwife and 
pharmacist. The rating was done using  Naranjo 
algorithm15 and the consensus among the panel 
members was used as the fi nal rating. The study 
was approved by the Human Ethics Committee of 
the study hospital. Written informed consent was 
obtained from the patients prior to observation.
Patient characteristics and side effect data 
were summarized using descriptive statistics. The 
proportion of misoprostol’s side effect incidence 
between two modes of delivery was compared 
using Z-test. Statistical data analysis was 
undertaken using statistical Product and Service 
Solutions (SPSS) for Windows version 22.0. The 
level of signifi cance was set at a probability value 
of p < 0.05.
RESULTS
There were 40 patients observed in each 
group during this three-month study. Patients’ 
maternal and obstetric characteristics are 
summarized in Table 1. As seen in Table 1, there 
was no discernible difference in maternal age 
and gestational age between the two groups. 
With regard to parity, patients in CS group tend 
to have more birth experience with nearly 40% 
having their third parity compared with 22.5% 
of those in VD group. Four patients in CS group 
had comorbidities (i.e. hypertension, human 
immunodefi ciency virus infection, hepatitis B, 
brain tumour) with only one patient taking regular 
medicine. Meanwhile, none of the patients in the 
VD group reported any comorbidities and took 
any routine medicine.
 n =       N
1 + Ne2
Denote:
n  : sample size for each group
N  : Population size
e  : Margin of error
Sample size for group of vaginal delivery: 
   n = N     =           40             =   40    = 36.36 ~ 40 patients
(1 + Ne2)      ( 1 + 40 x 0.052 )       1.1        
Sample size for group of cesarean section:
   n = N      =           45            =    45    = 40.9 ~ 40 patients
(1 + Ne2)      ( 1 + 45 x 0.052 )        1.1               
Table 1. Patients' Maternal and Obstetric Characteristics
Table 2. Patients’ Pre-and Postpartum Clinical Data 
Maternal age in years (±SD)
Gestational age in weeks (±SD)
Parity, N (%)
1
2
≥3
Presence of comorbidities, N (%)
Routine consumption of medicines, N (%)
Temperature, N (%)
Normal (36.1-37.2 ⁰C)
Above normal (>37.2 ⁰C)
Pain Scale (5-point), N (%)
3
4
Hemoglobin level, N (%)
8-12 g/dL
12-16 g/dL
Hamorrhage volume, N (%)
>500 mL
>1000 mL
40 (100.0)
-
40 (100.0)
-
25 (62.5)
15 (37.5)
-
-
5 (12.5)
35 (87.5)
40 (100.0)
-
39 (97.5)
1 (2.5)
40 (100.0)
-
37 (92.5)
3 (7.5)
39 (97.5)
1 (2.5)
22 (55.0)
18 (45.0)
-
-
1 (2.5)
39 (97.5)
39 (97.5)
1 (2.5)
40 (100.0)
-
40 (100.0)
29.05 (±7.172)
37.65 (±1.099)
15 (37.5)
16 (40.0)
9 (22.5)
-
-
29.58 (±7.510)
36.83 (±2.899)
10 (25.0)
15 (37.5)
15 (37.5)
4 (10.0)
1 (2.5)
Characteristics
Clinical Parameters
Vaginal Delivery Group
(N=40 Patients)
Vaginal Delivery Group 
(N=40 Patients)
Cesarean Section Group 
(N=40 Patients)
Prepartum PrepartumPostpartum Postpartum
Cesarean Section Group 
(N=40 Patients)
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Side Effects of Misoprostol
All patients in the VD group received 
misoprostol per rectal 400 mcg given in a single 
dose. Meanwhile, the majority of CS patients 
(N=38, 95.0%) was given a higher total dose of 
misoprostol (i.e. 600 mcg single dose) via rectal 
route and two patients received total dose 800 
mcg divided into two doses (600 mcg followed 
by 200 mcg). The second dose was given due to 
persistent hamorrhage despite the administration 
of fi rst dose. Patients were observed before and 
after delivery to evaluate the patient's clinical 
status and identify the presence of misoprostol's 
side effects. The clinical data are detailed in Table 
2. 
It can be seen from Table 2 that after delivery 
the majority of VD patients (87.5%) and nearly 
all CS patients experienced increased body 
temperature above the normal range. Both 
groups showed a similar pattern in pain severity 
where there was no change in pain scale before 
and after delivery. Nonetheless, one patient in 
CS group reported slightly more severe pain (i.e., 
scale of 4) compared to other patients in both 
Concerning the probability of side effect 
occurrence, there were slight differences between 
VD and CS patients. The panellist rated all side 
effects in VD patients as probable. Meanwhile, 
more than 70% (N=115/164 ) of the side effects 
in CS patients were regarded as probable leaving 
the rest of the proportion as defi nite. Further, 
abdominal pain and fatigue, which were absent 
in VD patients, were rated as defi nite in CS group.
DISCUSSION
Misoprostol can be administered through many 
routes including oral, vaginal, sublingual, buccal 
groups. Concerning the hemoglobin (Hb) level, 
just over 60% of VD patients had Hb < 12 g/dL and 
the proportion increased enormously to 97.5%. 
The similar condition was documented in the CS 
group with all patients having low postpartum 
Hb level. The high proportion of patients with 
decreased Hb level could be partly explained due 
to the volume of blood loss (i.e.>500 mL in the 
VD group and >1000 mL in CS group).
Thirty-four patients (85.0%) patients in the 
VD group experienced side effects, whilst all CS 
patients reported at least one side effect after 
receiving misoprostol. There was no signifi cant 
difference in the proportion of patients having 
side effects in the two groups (p=0.366). Totally, 
there were 135 and 164 side effects in the VD 
group and CS group, respectively. The details 
of side effects of misoprostol in the two study 
groups can be seen in Table 3. As described in 
Table 3, gastrointestinal side effects (e.g. nausea, 
vomiting, diarrhoea) accounted for the most 
frequent side effects in the two groups. In terms 
of side effect profi le, there was no discernible 
difference between the two groups. However, 
abdominal pain and fatigue were observed in CS 
patients only.
or rectal. A pharmacokinetic study comparing the 
profi les of misoprostol administration in three 
different routes (i.e. oral, rectal, vaginal) showed 
that vaginal misoprostol had a greater area under 
curve (AUC) and circulated in the body longer 
than the oral route. Rectal misoprostol showed 
similar profi les to the vaginal route but with 
lower AUC. Oral misoprostol had a higher peak 
plasma concentration and more rapid absorption 
than either vaginal or rectal route highlighting 
the higher rates of gastrointestinal-related side 
effects (nausea, diarrhoea) associated with oral 
misoprostol compared to the vaginal and rectal 
route. 11, 16 The present study used misoprostol 
Table 3. Side Effects of Misoprostol Per Rectal in Vaginal Delivery and Cesarean Section
*Z-test was applied to compare the proportion of each side effect occurrence experienced by patients in the group of vaginal delivery versus 
that of cesarean section.
Nausea
Vomiting
Pyrexia
Shivering
Diarrhea
Abdominal pain
Headache
Fatigue
31 (77.5)
31 (77.5)
27 (67.5)
20 (50.0)
10 (25.0)
-
16 (40.0)
-
34 (85.0)
34 (85.0)
33 (82.5)
23 (57.5)
8 (20.0)
2 (5.0)
29 (72.5)
1 (2.5)
0.438
0.432
0.366
0.432
0.454
0.454
0.228
0.477
Vaginal Delivery Group
(N=40 Patients)
Types of Side Effects
N (%)
Cesarean Section Group 
(N=40 Patients)
P-value
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tablet designed for oral administration instead 
of the specifi cally-designed rectal formulation. 
However, a study done by Khan and colleagues 
revealed that oral misoprostol tablet can be 
absorbed by rectal and vaginal route.16
It is challenging to compare our fi ndings 
with other studies despite numerous studies 
have been done to evaluate misoprostol’s side 
effects. To the best of our knowledge, little 
research has been done to compare the side 
effects of misoprostol between VD and CS 
patients. Regarding the profi le of side effect, 
the results of this present study were in line 
with the WHO Adverse Reaction Database that 
the most common frequent adverse events 
related to misoprostol were as follows: diarrhoea, 
abdominal pain, nausea, hamorrhage, abortion, 
vomiting, dyspepsia, fl atulence, abortion, 
vomiting, dizziness, menorrhagia, vaginal 
hemorrhage and fever.17 Similarly, pooled data 
from Cochrane review showed that misoprostol 
given in treatment doses had increased risk of 
side effects in comparison to placebo. According 
to the review, patients taking misoprostol had 
approximately two-fold risk to experience 
vomiting and shivering, and three-fold risk of 
pyrexia.  Nevertheless, the reported side effects 
were transient in nature.11
The safety profi le of misoprostol in 
obstetrics is linked to the pharmacokinetic 
profi le of PGE1analogue.9 In addition to its 
uterotonic mechanism, misoprostol has shown 
pharmacologic effects on several organ systems. 
It can inhibit platelet-activating factors and affects 
metabolic and physiologic processes.18 PGE1 like 
misoprostol acts on the central thermoregulation 
centres which may explain the incidence of 
pyrexia in misoprostol use.19 A systematic meta-
analysis done involving 33 trials found that the 
incidence of pyrexia after administration of 
misoprostol is largely determined by its dosage 
and route.20 That study reported that the highest 
incidence of pyrexia was noted in sublingual 
route (15%) with lower rates with the oral (11.4%) 
and rectal (4%)  which was contradictory with 
our fi nding showing high incidence of pyrexia 
more than 60%.  In line and colleagues found 
sublingual route had the highest bioavailability 
of all administration modes and this route was 
associated with the highest incidence of side 
effects compared to other routes.21 Further, 
the study underlined vital fi nding that patients 
taking misoprostol had the fi ve-time risk of 
pyrexia as opposed to those given placebo or 
other uterotonic agents.20PGE1 effect on central 
thermoregulatory system also has an impact 
on the incidence of shivering. A randomized 
placebo-controlled trial of misoprostol for PPH 
prevention reported shivering was more common 
in the misoprostol group than in that of placebo 
(19% vs 5% respectively).22Corresponding to the 
result of our study, higher rates of shivering were 
uncovered in other studies where shivering was 
documented in 32%-57% of women receiving 
misoprostol.13,14 Other common side effects of 
misoprostol included diarrhoea and nausea which 
occurred due to the impact of prostaglandin on 
the smooth muscle of the gastrointestinal tract 
including increased orocaecal transit time.23
The current study also revealed that patients in 
CS group received a higher dose of misoprostol 
(600 mcg as a single dose and two patients took 
total dose of 800 mc) than those in VD group (i.e., 
400 mcg). A meta-analysis comparing misoprostol 
400 mcg vs 600 mcg showed no evidence of 
using misoprostol with higher dose for reducing 
blood loss. Moreover, the incidence of pyrexia 
was higher among women receiving misoprostol 
compared with those taking other uterotonics. 
Higher dose of misoprostol (600 mcg) was 
associated with more incidence of pyrexia than 
the lower dose (400 mcg).17 Our study confi rmed 
the fi nding of the meta-analysis in which CS 
patients showed higher rate of pyrexia (82.5%) 
than those in the VD group (67.5%). Further, it has 
been found that studies reporting maternal death 
after taking misoprostol, the patients in those 
studies were administered with higher dose (i.e., 
≥600 mcg).13,14,17 In fact, some trials uncovered 
signifi cant fi nding that there was no signifi cant 
effi cacy between misoprostol 400 mcg vs higher 
doses. Conversely, the fi ndings highlighted the 
safety concerns pertinent to the use of high dose 
of misoprostol as the frequency and severity of 
adverse events were dose-related.17, 24
It is quite unfortunate that there is no clinical 
pathway for PPH management in the study 
hospital. The fi ndings of this study confi rm 
the existing evidence to obstetricians and 
gynecologists as to the safety of misoprostol 
for treating PPH. Further, the results can be 
used as essential information for the clinicians 
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to develop clinical pathway in the study hospital 
to guide them when treating patients with PPH. 
Nonetheless, there are some limitations in the 
study. Firstly, this study was conducted in one 
hospital with modest number of samples which 
diminished the generalization of the fi ndings. Our 
fi ndings highlight that more research is required 
to better understand the rate and pattern of 
misoprostol’s side effects in two modes of 
delivery. Future studies should include larger 
sample size with various routes of misoprostol and 
multiple institutions to provide a broader picture 
of the side effects and to identify the infl uence 
of delivery mode on the side effects. Secondly, 
the panellists rating the side effect probability 
were selected for convenience and there was 
no formal training provided. Nevertheless, the 
panellists were deemed to have the adequate 
clinical knowledge and professional experience, 
and the panellists were asked to read through the 
Naranjo algorithm prior to the panel meeting. The 
results might be different if the formal training 
on how to use the Naranjo algorithm had been 
provided to the panellists.
CONCLUSIONS
In summary, the study uncovered high incidence 
of misoprostol-related side effects both in 
VD and CS patients and the rate of incidence 
was not signifi cantly different between the 
two delivery modes. In addition, there was no 
discernible difference in the profi le of side effects 
documented in the two groups. This study raises 
the concern on the importance of judicious use 
of misoprostol for obstetric and gynecological 
indications in appropriate clinical settings to 
ensure its effectiveness and safety. In addition, 
the frequent occurrence of side effects related 
to its use requires active pharmacovigilance 
involving the front-line healthcare professionals 
particularly doctors, nurses and pharmacists.
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